Introduction {#sec1_1}
============

Contrast-induced acute kidney injury (CIAKI) is one of the major critical complications of coronary angiography (CAG) and/or percutaneous coronary intervention (PCI), and is associated with increased morbidity and mortality \[[@B1],[@B2]\].

The overall incidence of CIAKI in patients with chronic kidney disease (CKD) is extremely higher, at 10--25% \[[@B3],[@B4]\], than in the general population. Diabetes mellitus, high-dose administration of contrast media, hypotension, anemia, and CKD are reported as the risk factors for CIAKI \[[@B4]\]. To date, there is no sound evidence supporting the routine use of prophylactic drugs to prevent CIAKI; however, it is potentially possible to diminish the incidence by reducing the volume of contrast media.

Since recently, technical advances allow performing CAG or PCI with a very small amount of contrast media. The toxicity of contrast media on the kidneys is dose dependent \[[@B5]\], and a recent report revealed that a volume of contrast medium of ≥155 ml is a risk for CIAKI \[[@B6]\].

The pathogenesis of CIAKI is considered to be mainly dependent on renal hypoperfusion and ischemia \[[@B7],[@B8]\]. Carperitide, a member of the natriuretic peptide family with a vasodilating function \[[@B9],[@B10]\], was found to have various renoprotective effects, such as improvement of renal plasma flow, reducing the plasma levels of several vasoconstrictors \[[@B11],[@B12],[@B13]\]. Morikawa et al. \[[@B6]\] reported that the beneficial effect of low-dose carperitide on renal function is maintained for up to 1 month after contrast medium use. However, another study failed to prove any beneficial effect of carperitide on the incidence of CIAKI \[[@B14]\].

The aim of this prospective, randomized, open-label, blinded endpoint (PROBE) study was to determine whether low-dose carperitide has a prophylactic effect against CIAKI under CAG/PCI with a minimum volume of contrast medium in patients with CKD.

Materials and Methods {#sec1_2}
=====================

Study Population {#sec2_1}
----------------

We enrolled a total of 125 consecutive CKD patients undergoing CAG or PCI. CKD was defined as a baseline estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m^2^, which was calculated by the Modification of Diet in Renal Disease formula modified for Japanese subjects: eGFR = 194 × serum creatinine^−1.094^ × age^−0.287^ × 0.739 (if female) \[[@B15],[@B16]\]. The exclusion criteria included hypersensitivity to contrast media or carperitide; a baseline systolic blood pressure \<110 mm Hg; the use of vasopressors before the procedure; current hemodialysis; planned post-contrast medium dialysis; major surgery or contrast medium use within 10 days before the study; acute coronary syndrome; multiple myeloma; parenteral use of diuretics, and the administration of N-acetylcysteine, metformin, sodium bicarbonate, fenoldopam, mannitol, or nonsteroidal anti-inflammatory drugs (NSAIDs). We excluded the patients who required cardiac mechanical support (intra-aortic balloon pumping or percutaneous cardiopulmonary support) during the procedure.

We calculated the sample size assuming a CIAKI rate of 20% in the control group based on the incidence rate previously reported in CKD patients undergoing CAG \[[@B3],[@B4]\]. Also, we assumed that the incidence of CIAKI decreases to almost one seventh through the administration of carperitide \[[@B13]\]. Based on these assumptions, we calculated that 57 patients were needed in each treatment group to detect a statistically significant difference between treatment groups using the log-rank test with α = 0.05 (two-sided) and 1 -- β = 0.80.

The study protocol and chart reviews were approved by our institutional ethics committee. Written informed consent was given by all patients prior to the procedure.

Study Protocol {#sec2_2}
--------------

Patients were randomly assigned to receive either carperitide (Daiichi-Sankyo Co., Ltd., Tokyo, Japan) in addition to intravenous hydration with 1.0 ml/kg/h of saline (carperitide group) or only hydration with saline (control group) for 12--18 h before and for 6 h after contrast administration. Carperitide was dissolved in a 5% carbohydrate solution and adjusted to 0.025 μg/kg/min. Iohexol (Omnipaque 350; Daiichi-Sankyo Co., Ltd.), a nonionic, low-osmolality contrast medium, was used in all patients. When the systolic blood pressure decreased below 90 mm Hg, carperitide was reduced to half a dose. When we recognized a consistent decrease in the systolic blood pressure (to \<90 mm Hg) or when the patients' symptoms were dependent on blood pressure oscillations, we excluded the patients from this study.

The primary endpoint was the incidence of CIAKI defined as a 25% increase in creatinine or an increase in creatinine by 0.5 mg/dl from baseline at the maximum value obtained within 48 h after the procedure \[[@B4],[@B5]\]. The serum creatinine and cystatin C levels were measured at 12--24 h before the procedure, and at 24--48 h and 1 week after the procedure. The secondary endpoint was the changes in the serum creatinine and serum cystatin C concentrations at 1 week after procedure.

Statistical Analysis {#sec2_3}
--------------------

The STATA/SE11 software program was used for all statistical analyses. We tested the distribution of continuous variables for normality with a one-sample Kolmogorov-Smirnov test. Continuous variables were presented as the means (standard deviations), and differences between the two groups were evaluated by Student\'s unpaired t test or the Wilcoxon test if the distribution was abnormal. Comparisons across the two groups were performed by the χ^2^ test. We used a logistic regression analysis for the multivariable analysis. After initial therapy, the statistical analysis was based on an intention-to-treat analysis.

Results {#sec1_3}
=======

Seven patients (2 refused to participate in the study, 5 did not meet the inclusion criteria) did not participate in this study. Two patients with symptomatic hypotension were excluded because of their intolerance to carperitide. After CAG, 4 patients (3 who received a dose of contrast medium \>150 ml, and 1 who required intra-aortic balloon pumping) were excluded. Therefore, 112 patients were eligible for this study (carperitide group: n = 59, placebo group: n = 53) (fig. [1](#F1){ref-type="fig"}).

Table [1](#T1){ref-type="table"} shows the baseline clinical characteristics of the enrolled patients. There were no significant differences between the two groups. Also, the patients' baseline renal function was comparable.

The volume of contrast medium used (table [2](#T2){ref-type="table"}) was similar in both groups (carperitide group: 67.4 ± 38.2 ml vs. control group: 64.8 ± 20.5 ml, p = 0.661). When compared with the control group, carperitide infusion produced a significant decrease in the systolic blood pressure at 12 h \[−3.5 (−7 to 2) vs. −14 (−20 to −8.5) mm Hg, p \< 0.001\]. The incidence of a critical systolic blood pressure reduction, defined as a systolic blood pressure reduction ≤−20 mm Hg, was significantly higher in the carperitide group than in the control group (p \< 0.001).

There were no significant differences for the primary outcome of the development of CIAKI between the groups (carperitide group: 8.5% vs. control group: 5.7%, p = 0.564) (fig. [2](#F2){ref-type="fig"}). Of importance, only an increase in serum creatinine \>25% occurred as an indicator of CIAKI, and there were no patients who developed CIAKI strictly defined as an increase in serum creatinine of ≥0.5 mg/dl.

According to the secondary endpoint, the adverse effects of contrast medium on renal function were also similar in both groups. Table [3](#T3){ref-type="table"} shows the changes in renal functional markers. In the carperitide group, there was a significant deterioration in the serum creatinine, eGFR, and serum cystatin C levels compared to the control group at 24--48 h after the administration of the contrast medium (p = 0.002, 0.006, 0.001, respectively). In contrast, the serum creatinine level showed a tendency to decrease in the carperitide group at 1 week after contrast medium use, but not significantly so.

A univariate analysis of the incidence of CIAKI in the carperitide group revealed that hypotension defined as a severe systolic blood pressure reduction by ≤−20 mm Hg was a significant predictor \[odds ratio (OR) 15.6 (1.58--154.28), p = 0.019\] (table [4](#T4){ref-type="table"}). When all variants of the patients' age, diabetes mellitus status, angiotensin II receptor blocker (ARB) and statin use, and hypotension detected by the univariate analysis were included in the multivariate model, hypotension was an independent predictor of the development of CIAKI in the carperitide group \[OR 31.87 (1.93--525.58), p = 0.015\]. Furthermore, all patients who developed CIAKI in the carperitide group and 75% of the patients who developed CIAKI in both groups were treated with calcium channel blockers. Although the incidence of CIAKI in the carperitide group without hypotension was low, it was comparable to that in the placebo group (2.4 vs. 5.7%, respectively, p = 0.432) (fig. [3](#F3){ref-type="fig"}).

Discussion {#sec1_4}
==========

The pathogenesis of CIAKI is considered to be linked to the cytotoxic effects of contrast media and renal vasoconstriction. In the present study, we showed that CAG with low-dose contrast medium decreased the incidence of CIAKI by about 50% compared to previous reports and none of our CKD patients with CAG developed strictly defined CIAKI (≥0.5 mg/dl serum creatinine), which is reported to be a more sensitive definition for mortality and morbidity in patients with CIAKI \[[@B17]\]. Carperitide, a renal-specific vasodilator, has been reported to have preventive effects on contrast-induced renal injury because of improvement of renal perfusion \[[@B18]\]. Contrary to the previously reported protective effects of carperitide, our current results did not demonstrate the advantages for CIAKI. A sub-analysis of CIAKI in the carperitide group showed an impact of hypotension, which was suggested to disturb the renoprotective effects of carperitide. Also, our sub-analysis revealed that combination therapy using calcium channel antagonists with carperitide could potentially predict the development of CIAKI. Glomerular hypoperfusion induced by systemic arterial pressure reduction due to treatment with dual vasodilators is suggested to result in glomerular dysfunction within 48 h after contrast medium use.

Mehran et al. \[[@B19]\] reported the utility of a CIAKI risk stratification score based on 8 available variables, and we can improve the procedure-related factors including the contrast volume. The present study indicates that decreasing the volume of contrast medium is indispensable for the prophylaxis of CIAKI, especially in CKD patients. When the contrast volume is suppressed to \<100 ml, a critical blood pressure reduction exerts adverse effects on the development of CIAKI. The results of our sub-analysis emphasize the need for avoiding excessive use of vasodilators in order to maintain the renal circulation. As the incidence of hypotension was higher in the carperitide group, carperitide use should be avoided when the contrast medium volume is suppressed. The determination of an adaptable dose of carperitide, without hypotension, is essential for an effective and safe use of carperitide in patients with CAG/PCI.

Study Limitations {#sec2_4}
-----------------

First, the diagnosis of CIAKI depended on the peak value of the serum creatinine concentration within 48 h after contrast medium use \[[@B20]\]. However, because of our institutional limitations concerning the frequency and timing of blood collection, the degree of the elevation of creatinine might have been underestimated. Second, this study was a single-center study and was not blinded. Third, the incidence of CIAKI was lower than predicted under procedures using a small amount of contrast medium.
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![The incidence of CIAKI was a little higher in the carperitide group than in the control group, but the difference was not statistically significant.](nne-0002-0303-g02){#F2}

![The incidence of CIAKI was higher in the control group than in the carperitide group without severe blood pressure reduction, but the difference was not statistically significant.](nne-0002-0303-g03){#F3}

###### 

Baseline characteristics of study patients

                                           Carperitide group (n = 59)   Control group (n = 53)   p value
  ---------------------------------------- ---------------------------- ------------------------ ---------
  Age, years                               74 (8.9)                     73.0 (6.3)               0.566
  Male, %                                  68                           83                       0.080
  Body mass index                          23.9 (3.1)                   23.6 (3.4)               0.682
  Systolic blood pressure, mm Hg           129.9 (17.6)                 135.1 (20.7)             0.152
  Hypertension, %                          83                           77                       0.449
  Diabetes mellitus, %                     59                           45                       0.137
  History of myocardial infarction, %      15                           15                       0.981
  History of congestive heart failure, %   8                            9                        0.859
  Medication, %                                                                                  
   ACE inhibitors                          18                           8                        0.158
   ARBs                                    56                           63                       0.513
   Calcium channel blockers                52                           42                       0.306
   Diuretics                               34                           38                       0.718
   Statins                                 68                           65                       0.721
  LVEF, %                                  62.6 (12.4)                  59.0 (15.7)              0.198
  Current smoker, %                        24                           38                       0.121

Data are presented as means (SD) for continuous variables, and percentages for categorical variables. ACE = Angiotensin-converting enzyme; LVEF = left ventricular ejection fraction.

###### 

Contrast volume and c hanges in blood pressure of study patients

                                             Carperitide group (n = 59)   Control group (n = 53)   p value
  ------------------------------------------ ---------------------------- ------------------------ ---------
  Contrast medium volume, ml                 67.4 (38.2)                  64.8 (20.5)              0.661
  Change in systolic blood pressure, mm Hg   −14 (−20 to −8.5)            −3.5 (−7 to −2)          \<0.001
  Incidence of hypotension^1^, %             31                           2                        \<0.001

Data are presented as means (SD) or medians (interquartile ranges) for continuous variables and percentages for categorical variables.

Incidence of hypotension is defined as a systolic blood pressure reduction ≤−20 mm Hg from baseline.

###### 

Changes from baseline in serum creatinine, eGFR, and serum cystatin C

                            Carperitide group (n = 59)   Control group (n = 53)   p value
  ------------------------- ---------------------------- ------------------------ ---------
  Serum creatinine, mg/dl                                                         
   Baseline                 1.16 (0.99--1.27)            1.18 (1--1.44)           0.493
   Change within 48 h       0.05 (−0.03 to 0.13)         −0.03 (−0.08 to 0.07)    0.002
   Change at 1 week         −0.03 (−0.09 to 0.04)        0.01 (−0.06 to 0.07)     0.054
  eGFR, ml/min/1.73 m^2^                                                          
   Baseline                 44.4 (9.2)                   45.4 (10.4)              0.574
   Change within 48 h       −2.0 (6.1)                   0.8 (4.3)                0.006
   Change at 1 week         0.9 (5.6)                    −0.4 (4.3)               0.169
  Serum cystatin C, mg/l                                                          
   Baseline                 1.47 (1.26-1.64)             1.36 (1.23--1.7)         0.630
   Change within 48 h       0.09 (−0.01 to 0.18)         −0.03 (−0.11 to 0.07)    0.001
   Change at 1 week         −0.01 (−0.08 to 0.04)        −0.01 (−0.1 to 0.05)     0.242

Data are presented as means (SD) or medians (interquartile ranges).

###### 

Univariate and multivariate analysis for CI AKI in the carperitide group

                                                              CIAKI, %   Univariate analysis   Multivariate analysis                                  
  ----------------------------------------------------------- ---------- --------------------- ----------------------- ------- ---------------------- -------
  Age \>70 years                                              80         78                    1.14 (0.12--11.21)      0.909   1.08 (0.1--33.16)      0.960
  Diabetes mellitus                                           80         57                    2.97 (0.31--28.35)      0.325   10.49 (0.40--275.51)   0.159
  Dyslipidemia                                                80         69                    1.83 (0.19--17.71)      0.599                          
  Hypertension                                                80         82                    0.91 (0.09--9.03)       0.940                          
  ARBs                                                        20         59                    0.17 (0.02--1.64)       0.126   0.78 (0--1.61)         0.099
  Statins                                                     60         70                    0.63 (0.10--4.15)       0.630   0.22 (0.13--3.35)      0.274
  Incidence of hypotension[^1^](#T4F1){ref-type="table-fn"}   80         30                    15.6 (1.58--154.28)     0.019   31.87 (1.93--525.58)   0.015
  LVEF(≥40%)                                                  80         93                    0.32 (0.29--3.59)       0.333                          
  Contrast medium \>65 ml                                     40         35                    1.23 (0.19--8.00)       0.830                          
  History of myocardial infarction                            20         15                    1.44 (0.14--14.57)      0.758                          

LVEF = Left ventricular ejection fraction; CI = confidence interval.

Incidence of hypotension is defined as a systolic blood pressure reduction ≤−20 mm Hg from baseline.
